Nurotron Completes Hundreds of Millions RMB Strategic Equity Investment to Accelerate Global Expansion and Neuroelectronic Business Development

Recently, the investment platforms under Hangzhou State-owned Capital Investment & Operation Co., Ltd. and Hangzhou Yuhang Venture Capital Co., Ltd. have officially completed a strategic equity acquisition of Zhejiang Nurotron Biotechnology Co., Ltd. worth hundreds of millions of yuan, marking the formal entry of municipal and district-level state-owned assets as key shareholders of Nurotron.

This proactive deployment of state-owned capital will help further improve Nurotron’s corporate governance structure, accelerate the implementation of its global strategy and the long-term development of its neuroelectronics business, and facilitate Nurotron’s deeper integration into the industrial ecosystem of the Hangzhou West Science and Technology Innovation Corridor. Meanwhile, this investment fully demonstrates the strong support of the Hangzhou Municipal and Yuhang District governments for the private sector, their strategic positioning in core scientific and technological innovation industry chains, their steadfast promotion of welfare initiatives for persons with disabilities, and their unwavering pursuit of the goal of common prosperity.

Zhejiang Nurotron Biotechnology Co., Ltd., established in 2006, is a national “Key Little Giant” enterprise specializing in the research and development, manufacturing, and sales of neuroelectronic medical devices. The company has consistently adhered to independent R&D, comprehensively expanding its product portfolio and applications around core technologies. It has successfully broken the monopoly held by Western countries in the field of cochlear implant technology. Nurotron was awarded the Second Prize of the National Science and Technology Progress Award in both 2015 and 2024, and has participated in multiple major projects under China’s Ministry of Science and Technology from the 11th Five-Year Plan to the 14th Five-Year Plan.

Currently, Nurotron’s cochlear implant products hold a 20% market share in China. Over 20,000 individuals with hearing impairment both domestically and abroad have received Nurotron cochlear implants, spanning an age range from 1 to 80 years. The products are exported to numerous countries across Europe, the Americas, and Asia. Nurotron has deeply studied and internalized General Secretary Xi Jinping’s important expositions and instructions on disability affairs. Upholding the development vision of “continuously advancing the cause of persons with disabilities” and “promoting their comprehensive development and common prosperity,” the company adheres to its corporate mission of “enabling the deaf to hear, the blind to see, and the immobile to stand.” Guided by the business philosophy of “technology for social good and empowering persons with disabilities toward common prosperity,” Nurotron remains at the forefront of supporting and serving the disability community through independent research and development and technological innovation.